The licensed technologies, which were co-developed by FluoroPharma and Massachusetts General Hospital (MGH) scientists, target multiple biological processes associated with Alzheimer’s disease. According to the available sources, currently, there is no single diagnostic test that proves a person has Alzheimer’s.
Kundakovic, FluoroPharma’s president, said: “The technology has the potential to be highly effective due to the agents enhanced accumulation in the brain. In combination with high resolution PET imaging, these agents may provide valuable information in patients where early diagnostic and therapeutic information is likely to have the greatest benefit.”